Financial reports

Annual reports

2020, 2019, 2018, 2017, 2016, 2015, 2014, 2013

Recent reports

22 July, 2021

Interim report Q2 2021

April – June Revenues amounted to MSEK 747.9 (688.9), corresponding to an increase of +9% for the period.The organic growth1 during the second quarter was +8%. The currency impact in the quarter was 0% while the acquisitions of the product portfolios Pevaryl® from Johnson & Johnson and Flux®, Decubal®, Apobase®, Lactocare® from Teva generated growth...

21 April, 2021

Interim report Q1 2021

January – March Revenues amounted to MSEK 713.0 (793.6), corresponding to a decrease of -10% for the period. The organic growth* during the first quarter was -16%. The currency impact in the quarter was -1% while the acquisitions of the product portfolios Proct® from Leo Pharma and Pevaryl® from Johnson & Johnson generated growth of...

30 March, 2021

Karo Pharma publishes the 2020 annual report

Today, on 30 March 2021, Karo Pharma is publishing its annual report for 2020 on the company’s website, www.karopharma.com. For further information, please contact: Jon Johnsson, CFO, 073-507 88 61, jon.johnsson@karopharma.com The Annual Report is published in Swedish and English. The Swedish version represents the original version and has been translated into English. This information...

18 February, 2021

Year-end report 2020

Q4, October – December Net sales amounted to MSEK 721.2 (649.3). This corresponds to an increase of 11% for the period. The organic growth* during the fourth quarter was +1%. The currency impact in the quarter was -1% while the acquisitions of the product portfolios Proct® from Leo Pharma and Pevaryl® from Johnson & Johnson...